The invention provides colostrum derived stem cell populations, compositions and supplements having antimicrobial properties for enhancing mammalian health and for treating or preventing microbial contamination or infection. Also provided are methods of producing these populations, compositions and supplements from a female mammal in an inflammatory state. Also provided are colostrum derived stem cell populations and method of inducing differentiation into neural cells in neural progenitor medium including mammalian cell culture medium supplemented with casein depleted fraction of whey derived from colostrum. Also provided are neural progenitor medium, population of in vitro differentiated neural cells and pharmaceutical compositions containing same for use in treating neurological disease or disorder.

The present invention describes in vitro methods for producing a cellular composition with in vivo bone forming potential.

The invention provides compositions comprising multipotent progenitor cells isolated from tonsillar tissue and differentiated cells derived therefrom and methods for using the cells for the treatment of diseases or disorders.

The present disclosure relates to a method for differentiating motor neurons from tonsil-derived mesenchymal stem cells, and a cell therapy agent using the same. The differentiation method of the present disclosure exhibits high differentiation potency into motor neurons, and thus enables a large quantity of motor neurons to be secured. Since the cells which are differentiated according to the present disclosure are obtained using discarded tonsillar tissues, there are fewer ethical issues. In addition, the cells are highly applicable as a cell therapy agent because they can be obtained easily in large quantities.

The present invention relates to a method for producing a spheroid form of tonsil-derived stem cells, the method enhances growth and differentiation efficiency of the tonsil-derived stem cells. The present method also produces a spheroid form of para-thyroid hormones. The method for producing a spheroid form of tonsil-derived stem cells enhances the proliferation rate of the stem cells per se and significantly increase differentiation potency into parathyroid cells.

The present invention relates to a method of cultivating mammalian cells. This method comprises cultivating the mammalian cells on a feeder layer, wherein the feeder layer comprises a stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord

Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating a population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.

The present invention relates to an epithelial stem/progenitor cell population isolated from the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types. The invention also relates to a pharmaceutical composition comprising such an epithelial stem/progenitor cell population or a cellular extract thereof.

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating a population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.